Grand Pharmaceutical Group (HKSE:00512) Interest Expense : HK$-205 Mil (TTM As of Dec. 2023)

View and export this data going back to 1995. Start your Free Trial

What is Grand Pharmaceutical Group Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Grand Pharmaceutical Group's interest expense for the six months ended in Dec. 2023 was HK$ -92 Mil. Its interest expense for the trailing twelve months (TTM) ended in Dec. 2023 was HK$-205 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Grand Pharmaceutical Group's Operating Income for the six months ended in Dec. 2023 was HK$ 1,288 Mil. Grand Pharmaceutical Group's Interest Expense for the six months ended in Dec. 2023 was HK$ -92 Mil. Grand Pharmaceutical Group's Interest Coverage for the quarter that ended in Dec. 2023 was 14.02. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Grand Pharmaceutical Group Interest Expense Historical Data

The historical data trend for Grand Pharmaceutical Group's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Grand Pharmaceutical Group Interest Expense Chart

Grand Pharmaceutical Group Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Interest Expense

Get a 7-Day Free Trial

-146.50

-115.42

-92.96

-137.49

-205.15

Grand Pharmaceutical Group Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Interest Expense	Get a 7-Day Free Trial															-69.29	-63.21	-74.28	-113.23	-91.91

Grand Pharmaceutical Group Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$-205 Mil.

Grand Pharmaceutical Group (HKSE:00512) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Grand Pharmaceutical Group's Interest Expense for the six months ended in Dec. 2023 was HK$-92 Mil. Its Operating Income for the six months ended in Dec. 2023 was HK$1,288 Mil. And its Long-Term Debt & Capital Lease Obligation for the six months ended in Dec. 2023 was HK$1,052 Mil.

Grand Pharmaceutical Group's Interest Coverage for the quarter that ended in Dec. 2023 is calculated as

Interest Coverage	=	-1	*	Operating Income (Q: Dec. 2023 )	/	Interest Expense (Q: Dec. 2023 )
	=	-1	*	1288.421	/	-91.912
	=	14.02

The higher the ratio, the stronger the company's financial strength is.

Grand Pharmaceutical Group (HKSE:00512) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Grand Pharmaceutical Group Ltd (HKSE:00512) » Definitions » Interest Expense

Traded in Other Exchanges

MX6A:Germany

Address

99 Queen's Road, Units 3302, 33rd Floor, The Center, Central, Hong Kong, HKG

Website

http://www.chinagrandpharm.com

Grand Pharmaceutical Group Ltd, formerly China Grand Pharmaceutical and Healthcare Holdings Ltd is a drug manufacturer. The company through its subsidiaries manufactures and sells pharmaceutical preparations and medical devices, biotechnology products, nutrition products, specialized pharmaceutical raw materials, and other products. Geographically, it derives a majority of revenue from China and also has a presence in America; Europe; Asia other than the PRC and others.

Executives

Shang Hai Yuan Da Chan Rong Tou Zi Guan Li You Xian Gong Si	2101 Beneficial owner
Hu Kaijun	2201 Interest of corporation controlled by you
East Ocean Capital (hong Kong) Company Limited	2101 Beneficial owner
Lion River I N.v.	2201 Interest of corporation controlled by you
Li Zhenfu	2201 Interest of corporation controlled by you
Gl Partners Capital Management Ltd.	2201 Interest of corporation controlled by you
Assicurazioni Generali Spa	2201 Interest of corporation controlled by you
Citic Group Corporation	2201 Interest of corporation controlled by you
Citic Limited	2201 Interest of corporation controlled by you
China Citic Bank Corporation Limited	2201 Interest of corporation controlled by you
Cncb (hong Kong) Investment Limited	2106 Person having a security interest in shares
Grand (hongkong) International Investments Holdings Limited
Chau Tung
Zhong Guo Yuan Da Ji Tuan You Xian Ze Ren Gong Si
Outwit Investments Limited

Grand Pharmaceutical Group (HKSE:00512) Headlines

No Headlines